Yahoo · Oct 31, 2026
AbbVie: 3 Key Takeaways for Long-Term Investors
Newer therapies must sustain double-digit growth to offset the impact of Humira's patent cliff, a test that shapes the dividend's long-term safety.
AB
NASDAQ · ABBV
AbbVie Inc.
Healthcare · Drug Manufacturers - General
$294.89
Up+$4.10 (+1.41%)
Updated Nov 1, 2026, 6:31 PM
SID Score
7.1/10
Composite research score
Smart Money
59/100
Neutral
- Market cap
- 410.09B
- P/E ratio
- 97.75
- Dividend yield
- 2.81%
- 52-week range
- $190.75 – $298.74
- Volume
- 6.9M
- Avg. volume
- 6.4M
Price performance · ABBV
ABBV price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
ABBV closed at $294.89 after 20 trading sessions, up 10.96% for the selected period.
- Last close
- $294.89
- Period change
- +10.96%
- Period low
- $265.76
- Period high
- $294.89
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $292.00 | $298.74 | $291.01 | $294.89 | 6.9M |
| Oct 29, 2026 | $291.00 | $292.67 | $288.04 | $290.79 | 4.33M |
| Oct 28, 2026 | $282.93 | $288.80 | $281.225 | $285.99 | 3.11M |
| Oct 27, 2026 | $283.88 | $287.32 | $283.12 | $286.39 | 3.27M |
| Oct 26, 2026 | $287.05 | $289.586 | $285.18 | $286.74 | 4.52M |
| Oct 23, 2026 | $284.58 | $286.765 | $282.30 | $285.64 | 4.63M |
| Oct 22, 2026 | $284.57 | $285.76 | $278.01 | $285.19 | 6.17M |
| Oct 21, 2026 | $287.63 | $288.9999 | $282.15 | $284.80 | 4.39M |
| Oct 20, 2026 | $286.90 | $290.98 | $285.00 | $289.08 | 5.18M |
| Oct 19, 2026 | $284.23 | $287.9299 | $282.59 | $282.68 | 4.17M |
| Oct 16, 2026 | $283.61 | $286.64 | $282.955 | $285.42 | 5.78M |
| Oct 15, 2026 | $288.28 | $291.40 | $282.81 | $283.40 | 7.62M |
| Oct 14, 2026 | $277.00 | $285.3999 | $275.97 | $283.48 | 5.63M |
| Oct 13, 2026 | $283.29 | $283.43 | $273.70 | $274.36 | 6.41M |
| Oct 12, 2026 | $277.65 | $281.30 | $276.01 | $281.12 | 5.59M |
| Oct 9, 2026 | $271.53 | $277.60 | $270.38 | $276.47 | 4.3M |
| Oct 8, 2026 | $270.98 | $272.515 | $265.71 | $272.42 | 5.49M |
| Oct 7, 2026 | $268.40 | $274.94 | $266.89 | $271.36 | 6.08M |
| Oct 6, 2026 | $267.74 | $268.8582 | $260.6197 | $266.69 | 4.5M |
| Oct 5, 2026 | $261.27 | $267.34 | $260.29 | $265.76 | 7.54M |
Latest ABBV news
The latest Smart Investors Daily articles mentioning ABBV.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ABBV research
Overview
Company profile and research snapshot.
Company profile
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $258.83
- Implied upside
- —
- Analysts
- 19
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 23, 2026 | Goldman Sachs | Neutral | — |
| Oct 21, 2026 | Barclays | Overweight | — |
| Oct 13, 2026 | RBC Capital | Outperform | — |
| Oct 9, 2026 | Guggenheim | Buy | — |
| Oct 9, 2026 | UBS | Neutral | — |
News briefing
Generated Nov 1, 2026, 3:00 PM
Why Is ABBV Up Today? Strong Q3 Earnings and Raised Guidance Drive Investor Confidence
AbbVie stock rose 1.41% today following a better-than-expected Q3 earnings report that prompted management to lift its 2026 full-year outlook. The pharmaceutical giant's immunology and neuroscience segments outperformed analyst expectations, while the company also announced a dividend boost that reinforces its commitment to shareholder returns.
Bottom line: AbbVie's Q3 earnings beat and guidance raise provide near-term support for the stock, particularly appealing to dividend-focused investors seeking stable income generation. However, investors should monitor macro headwinds from broader market weakness and validate whether the raised outlook reflects sustainable growth or simply raised expectations that could prove difficult to maintain in 2026.
Yahoo · Oct 31, 2026
Is AbbVie a Buy After Its Latest Earnings Report?
Behind a doubling in adjusted EPS sits a more modest picture -- and a dividend streak worth understanding.
Yahoo · Oct 31, 2026
Is Earnings Beat Altering The Investment Case For AbbVie Stock (ABBV)?
AbbVie reported third quarter 2026 sales of US$17.4b and net income of US$4.2b, raised full year revenue and adjusted EPS guidance, and approved a 5.2% quarterly dividend increase to US$1.82 per share starting with the February 16, 2027 payment. The stronger outlook rests on AbbVie’s immunology and neuroscience engines, with products like SKYRIZI, RINVOQ and newer launches offsetting pressure on older therapies such as Humira and Imbruvica, while the oncology and migraine pipelines...
Yahoo · Oct 30, 2026
AbbVie (ABBV) Q3 2026 Earnings Call Transcript
Skyrizi and Rinvoq drive double-digit growth as management raises full-year guidance.
AI research layers
Interpretive context generated from the platform’s current data sources.
AbbVie Inc. Stock Performance
AbbVie Inc. shares traded at $294.89, reflecting a daily decline of 1.32% per SID market data. Despite the session pullback, the stock has demonstrated sustained upward momentum across multiple timeframes, gaining 13.45% over the trailing one-month period, 20.31% over three months, and 31.69% over the past year. The 50-day moving average stands at $269.29, while the 200-day moving average sits at $237.93, indicating the stock is trading well above both key technical levels, according to SID market data. The 14-day relative strength index registers at 66.0, approaching but not yet reaching overbought territory. AbbVie's beta of 0.334 reflects significantly lower volatility relative to the broader market, consistent with defensive healthcare sector characteristics. Average daily trading volume stands at approximately 6.4 million shares, supporting adequate liquidity. The company's market capitalization currently totals approximately $410.1 billion.
AbbVie Inc. Valuation Analysis
AbbVie Inc. currently trades at a price-to-earnings ratio of 97.75, a level notably elevated relative to the broader Healthcare sector, per SID market data. The PEG ratio of 1.25 suggests valuation is more moderate when adjusted for expected earnings growth, indicating the market is pricing in meaningful forward expansion. The company's price-to-book ratio registers at negative 126.33, reflecting a negative book value on the balance sheet — a consequence of significant goodwill impairments and accumulated intangible asset amortization tied to its acquisition strategy, according to SEC filings. AbbVie maintains a dividend yield of approximately 2.87%, providing income-oriented investors with a notable yield premium relative to the S&P 500 average. The elevated trailing P/E ratio may partly reflect non-recurring charges depressing reported earnings, warranting examination of adjusted earnings metrics for a more representative assessment of underlying profitability and cash flow generation capacity.
Smart Money Activity for ABBV
AbbVie Inc. registers a composite smart money score of 59 with a neutral overall signal, per SID market data. The institutional component scores a maximum 25 out of 25, indicating robust and broad-based ownership among major asset managers and mutual funds, according to 13F institutional filings. The insider component also scores highly at 21.0 out of 25, supported by recent purchasing activity — SEC Form 4 filings reveal two insider transactions over the past 90 days, both classified as buys with zero sells, signaling constructive sentiment among corporate officers and directors. Dark pool activity scores a more modest 9.8 out of 25, suggesting comparatively limited off-exchange institutional accumulation during the measured period. Congressional trading interest remains low at 3.2 out of 25. The divergence between strong institutional and insider conviction on one hand, and subdued dark pool and congressional activity on the other, produces the neutral composite reading despite clear pockets of informed buying interest.
AbbVie Inc. Earnings Outlook
AbbVie Inc.'s most recent reported quarter delivered earnings per share of $3.82, exceeding analyst consensus estimates of $3.77 by $0.05, according to company earnings reports. The prior quarter showed a miss, with actual EPS of $3.65 falling short of the $3.77 estimate by $0.12. The quarter before that produced EPS of $2.65 against an estimate of $2.66, representing a marginal miss of $0.01. The upcoming quarterly report, scheduled for April 24, carries a consensus estimate of $3.01 per share, per analyst estimates. The sequential earnings trajectory from $2.65 to $3.65 to $3.82 reflects meaningful growth, potentially driven by expanding revenues from immunology and oncology franchises following the Humira biosimilar transition. AbbVie's mixed beat-and-miss pattern across recent quarters suggests execution remains uneven, though the magnitude of recent misses has been relatively contained compared to the upward earnings trend.
Wall Street Analyst Ratings for ABBV
Recent Wall Street analyst activity on AbbVie Inc. reflects a generally constructive but divided consensus, per SID consensus data. On October 23, Goldman Sachs maintained its Neutral rating, while Barclays reiterated an Overweight rating on October 21, according to Wall Street analyst reports. RBC Capital maintained an Outperform rating on October 13, and Guggenheim reiterated a Buy rating on October 9. UBS also maintained its Neutral stance on October 9. Notably, none of the five most recent analyst actions involved downgrades — all were reiterations of existing positions, suggesting stable conviction levels across the coverage universe. The ratings split evenly between constructive calls (Barclays Overweight, RBC Outperform, Guggenheim Buy) and more cautious stances (Goldman Sachs Neutral, UBS Neutral). This distribution indicates Wall Street broadly acknowledges AbbVie's growth pipeline and dividend profile while some firms view the current valuation, including the 97.75 trailing P/E ratio, as fully reflecting near-term fundamentals.
